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Cancer cell metabolism is often characterized by
a shift from an oxidative to a glycolytic bioenergetics
pathway, a phenomenon known as the Warburg
effect. miR-378* is embedded within PPARGC1b
which encodes PGC-1b, a transcriptional regulator
of oxidative energy metabolism. Here we show that
miR-378* expression is regulated by ERBB2 and
induces a metabolic shift in breast cancer cells.
miR-378* performs this function by inhibiting the
expression of two PGC-1b partners, ERRg and
GABPA, leading to a reduction in tricarboxylic acid
cycle gene expression and oxygen consumption as
well as an increase in lactate production and in cell
proliferation. In situ hybridization experiments show
that miR-378* expression correlates with progres-
sion of human breast cancer. These results identify
miR-378* as a molecular switch involved in the
orchestration of the Warburg effect in breast cancer
cells via interference with a well-integrated bioener-
getics transcriptional pathway.
INTRODUCTION
The shift from aerobic, oxidativemetabolism to glycolytic metab-
olism is a characteristic feature of cancer cells. To utilize glucose
for energy, cells metabolize glucose to pyruvate, which, under
normal oxygen conditions, is processed by the tricarboxylic
acid (TCA) cycle to reducing equivalents. Oxidative phosphory-
lation (OXPHOS) then produces ATP from the reducing equiva-
lents, resulting in the production of cellular energy. In hypoxic
conditions, pyruvate does not enter the TCA cycle but instead
is converted to lactic acid. This process of anaerobic glucose
metabolism produces much less energy per molecule of glucose
consumed, but occurs more rapidly than OXPHOS. Warburg
observed that even under normal oxygen conditions, cancer352 Cell Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Incells rely more on glycolysis than OXPHOS, a now well-recog-
nized hallmark of cancer cell metabolism (Warburg, 1956).
Recent work indicates that targeting metabolic pathways
could be a powerful method to inhibit cancer growth and
progression. Inhibiting lactate dehydrogenase A (LDH-A), the
enzyme which mediates the processing of pyruvate to lactate,
the final step of glycolysis, enhanced OXPHOS and respiration
while it suppressed cell growth and tumorigenicity in ERBB2-
initiated mammary epithelial tumor cell lines (Fantin et al.,
2006). This directly links cellular proliferative ability to the switch
between oxidative and anaerobic metabolism, and indicates the
significance of the regulation of glucose metabolism for cancer
cell maintenance and progression. Other studies have identified
specific genes within the TCA cycle whose expression is impor-
tant for inhibiting cancer cell proliferation. Succinate dehydroge-
nase (SDH) and fumarate hydratase (FH) were reported not only
to be necessary for normal OXPHOS but also to possess tumor
suppressor activity (Cervera et al., 2008; King et al., 2006), thus
providing evidence that the oxidative metabolic switch is not
only correlated with rates of cell proliferation but that these path-
ways are linked at a molecular level.
Members of the peroxisome proliferator activated receptor
(PPAR) g coactivator-1 (PGC-1) family (PGC-1a, PGC-1b, and
PPRC1) of transcriptional coactivator proteins are essential
regulators of cellular energy metabolism (Lin et al., 2005). The
PGC-1s work in concert with different transcription factors
involved in regulating cellular energy metabolism, most notably
the estrogen-related receptors (ERRa, -b, and -g), a family of
orphan nuclear receptors, and GA-binding protein a (GABPA),
which have been shown to orchestrate cellular programs of
OXPHOS and mitochondrial biogenesis (Dufour et al., 2007;
Gigue`re, 2008; Mootha et al., 2004; Schreiber et al., 2004).
miRNAs are short, endogenous, noncoding RNAs known to
inhibit the translation of their target transcripts. miRNAs are
now considered essential regulators of development and physi-
ological processes (Ma andWeinberg, 2008) and, by modulating
oncogenic and tumor suppressor pathways, miRNAs might also
play significant roles in cancer (Ventura and Jacks, 2009).
Recently, expression of the miR-378*/miR-378 hairpin was re-
ported to enhance cell survival and promote tumor growth and
angiogenesis in a pooled cell line through targeting thec.
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Figure 1. Expression of miR-378* in Human
Breast Cancer Cells
(A) Schematic representation of the PPARGC1B
locus indicating the location of miR-378* in the first
intron.
(B) Expression of miR-378* and miR-378 from an
intronic PPARGC1B genomic sequence. BT-474
human breast cancer cells were infected with
adenovirus containing the sequence of green fluo-
rescent protein (GFP) as control or that of the
miR-378*/miR-378 genomic sequence flanked by
approximately 200 bp on either side of the hairpin,
and quantitative polymerase chain reaction
(qRT-PCR) was used to detect the mature forms
of the two miRNAs. Results are presented as rela-
tive expression in cells expressing the intronic
PPARGC1B genomic sequence versus GFP as
normalized to U6 (set at 1).
(C) Decreased expression of PPARGC1B,
miR-378*, and miR-378 upon depletion of ERBB2
in SkBr3 cells. siRNA against ERBB2 (siE) results
in parallel downregulation of PPARGC1B mRNA
levels,miR-378*, andmiR-378 as determined via relative quantitation by qRT-PCR. Results are expressed as relative expression from values obtained in response
to the presence of siE normalized to values obtained with siC (scramble siRNA). Expression of control gene products 18S andU6 is set at 1. Knockdown of ERBB2
was quantified by western blotting, and tubulin was used as a control (inset).
(D) Decreased expression ofPPARGC1B andmiR-378* upon depletion of ERBB2 in BT-474 cells. Experiment was conducted as in (C). Data from a representative
experiment are shown. Data are represented as mean ± SEM. Unpaired student’s t test was used for evaluation of statistical significance in (B)–(D). *p < 0.05,
**p < 0.01, ***p < 0.001.
Cell Metabolism
miRNA Control of the Warburg Effecttranscription factor SuFu and Fus-1, suggesting that miR-378*
and/or miR-378 possess oncogenic potential (Lee et al., 2007).
However, little else is known about the molecular mechanisms
underlying miR-378* or miR-378 function in cancer cells. Herein,
we report that miR-378*, a miRNA embedded within the
PPARGC1b locus whose expression is under the control of the
oncogene ERBB2 and increases during breast cancer progres-
sion, targets mRNAs encoding two important regulators of
energy metabolism, ERRg and GABPA, and induces the War-
burg effect in breast cancer cells.
RESULTS
miR-378* Is Coexpressed with PPARGC1b in Human
Breast Cancer Cells
The PGC-1-driven transcriptional network is subject to signifi-
cant amounts of regulation, including at the transcriptional and
posttranslational levels, but a role for miRNAs in controlling this
network has yet to be described (Lin et al., 2005). Scanning the
genomic locations of knownmiRNAs revealed that the first intron
of PPARGC1b (PGC-1b) contains a miRNA hairpin with the
potential of generating two miRNAs, miR-378* and miR-378
(Figure 1A). We also noticed that the Pictar miRNA target predic-
tion algorithm (http://pictar.mdc-berlin.de/) predicts miR-378* to
target ESRRG (ERRg), one of the nuclear receptors coactivated
by PGC-1b. GABPA, a transcription factor directly downstream
of the ERRs in the PGC-1 pathway, was also a predicted target
of miR-378* according to both Pictar and TargetScan (http://
www.targetscan.org/) algorithms. Because of miR-378*’s func-
tional relationship to its host gene,PPARGC1b, and the observa-
tion that miRNAs located within introns are commonly cotran-
scribed with their host genes (Kim and Kim, 2007), we
hypothesized that miR-378* could be implicated in the regulation
of a transcriptional network with PGC-1b at its nexus.CellWe first sought to determine whether the predicted miRNA
genomic hairpin is processed into mature miRNAs in breast
cancer cells. BT-474 cells, an ERBB2-positive cell line of human
origin that also expresses PGC-1b, ERRa, ERRg, and GABPA,
were chosen for further study. BT-474 cells were infected with
an adenovirus containing the miR-378*/miR-378 genomic
sequence, and qRT-PCR was used to detect the mature forms
of the miRNAs. The expression data show that both mature
miR-378* and miR-378 were produced from the genomic
sequence (Figure 1B). These results indicate that the genomic
sequence does not promote the processing of one miRNA
over the other, and that both mature miRNAs are formed in the
context of breast cancer cells.
In contrast to PGC-1a, little is known about factors and
pathways regulating the expression of PGC-1b. However, it
has recently been shown that PGC-1b expression is upregulated
by c-Myc in renal carcinoma cells (Zhang et al., 2007), demon-
strating that PGC-1b expression can be regulated by oncogenic
signals. We next investigated whether PGC-1b expression
could be influenced by manipulating the oncogenic ERBB2
pathway that plays a preeminent role in tumors of the breast.
Indeed, siRNA knockdown of ERBB2 expression in SkBr3
human breast cancer cells led to a parallel decrease (50%) in
PPARGC1b and mature miR-378* and miR-378 expression
(Figure 1C). This regulatory pathway is also operational in the
BT-474 breast cancer cell line (Figure 1D). These results show
that PPARGC1b and its intronic miRNAs are coregulated, in
addition to linking the expression of these genes to changes in
ERBB2 levels.
miR-378* Targets Endogenous ESRRG and GABPA
Human ESRRG is predicted to be targeted by miR-378* at two
regions within its 30UTR (Figure 2A), while a single sequence
within the GABPA 30UTR is predicted to be recognized by theMetabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inc. 353
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Figure 2. miR-378* Targets Endogenous
ESRRG and GABPA and Reduces Their
Expression in Human Breast Cancer Cells
(A) Sequences present in the 30UTR of ESRRG tar-
geted by miR-378* and conservation across
species. The boxed sequences are complemen-
tary to the seed sequence of miR-378*.
(B) Sequences present in the 30UTR of GABPA
targeted by miR-378* and conserved across
species. The boxed sequences are complemen-
tary to the seed sequence of miR-378*.
(C) Expression of miR-378* decreases luciferase
reporter gene activity in COS-1 cells when linked
to the targeted segment of the 30UTR of ESRRG.
Mutation of the seed sequence within the target
sequence at position 4 (m4) abolishes the
miR-378*-dependent repression. Control miR is
a control miRNA mimic, and the control is empty
vector.
(D) Expression of miR-378* decreases luciferase
reporter gene activity in COS-1 cells when linked
to the targeted segment of the 30UTR of GABPA.
Mutation of the seed sequence within the target
sequence at position 3–6 (m3-6) abolishes the
miR-378*-dependent repression.
(E) mRNA levels of ESRRA, ESRRG, andGABPA in
BT-474 cells upon expression of miR-378* as
compared to cells expressing control miRNA
(measured by qRT-PCR and normalized to
RPLP0 [dashed line]).
(F) Protein levels of ERRa, ERRg, and GABPA in
BT-474 cells upon expression of miR-378* or
control miRNA as measured by western blotting.
Tubulin is a loading control.
(G) A miRNA inhibitor (miR-378*-I) blocks the
action of endogenous miR-378* in BT-474 cells.
mRNA levels of ESRRG and GABPA were
measured by qRT-PCR and normalized to
TUBA1A. Control-I, control hairpin inhibitor.
(H) miR-378*-I blocks the action of endogenous
miR-378* in BT-474 cells. Protein levels of ERRg
and GABPA were measured by western blotting.
RPLP0 is a loading control.
(I) ERBB2 knockdown leads to elevated expres-
sion of ESRRG and GABPA in SKBr3 cells. siRNA
against ERBB2 (siE) results in upregulation of
ESRRG and GABPA mRNA levels as determined
via relative quantitation by qRT-PCR. Results are
expressed as relative expression from values
obtained in response to the presence of siE
normalized to values obtainedwith siC. Expression
of control gene 18S is set at 1. For all bar graphs,
data are represented as the mean ± SEM.
Unpaired student’s t test was used for evaluation
of statistical significance. *p < 0.05, **p < 0.01,
***p < 0.001.
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miRNA Control of the Warburg EffectmiRNA (Figure 2B). Target site locations are numbered relative to
the start of the 30UTR. To validate ESRRG and GABPA as bona
fide targets of miR-378*, we cloned the miR-378* predicted
target regions within each gene’s 30UTR downstream of a Renilla
luciferase reporter gene. These reporter plasmids were then
cotransfected with either control miRNA or miR-378* and cell
extracts monitored for luciferase activity. Repression of lucif-354 Cell Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inerase activity, as compared to control, was observed for all
predicted target sites (Figures 2C and 2D) and completely abol-
ished for all targeted regions by themutation of one base at posi-
tion 4 of the seed sequence within the ESRRG target sequences
and at positions 3–6 of the GABPA target sequence, indicating
the specificity of the interaction between miR-378* and its target
regions. The same result was obtained for the mouse genes,c.
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miRNA Control of the Warburg Effectindicating that the targeting functions of miR-378* are conserved
between species (see Figure S1 available online). To determine if
miR-378* could target endogenous ESRRG and GABPA, we
measured RNA levels of ESRRA, ESRRB, ESRRG, and GABPA
in BT-474 cells transfected either with control miRNA or
miR-378*. We found that introduction of miR-378* decreases
the levels of ESRRG and GABPA transcripts at 2, 4, and
6 days posttransfection, but that the levels of ESRRA, which is
not a target of miR-378*, were unaffected (Figure 2E). ESRRB
transcripts were not detected. We confirmed this result at the
protein level by testing BT-474 cells transfected with control
miRNA or miR-378* either 2 days or 7 days after transfection
by western blotting. Again there was no noticeable change of
ERRa levels, while both ERRg and GABPA levels were
decreased upon miR-378* expression (Figure 2F). To further
verify the specificity of interactions between miR-378* and its
targets, we used a miRNA inhibitor to specifically block
miR-378* action. Upon transfection of BT-474 cells with
the miR-378* inhibitor, we detected a statistically significant
increase (30%, p % 0.01) in endogenous transcript levels of
both ESRRG and GABPA, indicating that inhibiting endogenous
miR-378* alleviates the repressive effect on its targets
(Figure 2G). Similarly, the reduction in endogenous transcript
levels of ESRRG and GABPA in response to miR-378* expres-
sion is rescued when miR-378* is cotransfected with the
miR-378* inhibitor (Figure 2G). Inhibition of endogenous
miR-378* also causes an increase in endogenous ERRg and
GABPA proteins (Figure 2H). Finally, knockdown of ERBB2 leads
to an increase in mRNA levels of both ESRRG and GABPA (Fig-
ure 2I). Taken together, these results indicate that ESRRG and
GABPA are genuine endogenous ERBB2 and miR-378* targets
in breast cancer cells and that, notably, the regulatory effect of
miR-378* upon ERR family members is specific to ESRRG.
miR-378* Regulates Metabolic Genes via Its Target,
ERRg
We next asked what role miR-378* would have in regulating the
PGC-1b/ERR pathway in cancer cells. Recent genome-wide
location analyses by ChIP-on-chip have identified ERRa and -g
as direct regulators of TCA cycle genes (Alaynick et al., 2007;
Charest-Marcotte et al., 2010; Deblois et al., 2009; Dufour
et al., 2007; Sonoda et al., 2007; Tremblay et al., 2010), suggest-
ing that changes in ERRg levels could have a direct impact on the
expression ofmetabolic genes in breast cancer cells and thereby
inducing a push toward the glycolytic pathway by affecting OX-
PHOS. Using a ChIP-based assay, we first established that
ERRg binds to regulatory regions located in the vicinity of TCA
cycle genes in BT-474 cells. ERRg binds to promoters or prox-
imal enhancers of genes encoding enzymes participating in
nearly all steps of the TCA cycle (Figure 3A). The expression of
most of these target genes is downregulated via knockdown of
ERRg by a specific siRNA, further validating a major role for
ERRg in the control of TCA cycle gene expression (Figures 3B
and 3D). ERRg also controls the expression of a subset of glyco-
lytic genes, as LDHA levels are increased in response to si-
ESRRG treatment, whereas LDHB expression is decreased
(Figure 3C). Since the LDHA isoform has been shown to play
a major role in neu-initiated mammary tumorigenesis (Fantin
et al., 2006) and considering that its expression is the highestCellof the LDH isoforms in BT-474 cells, it is possible that repression
of LDHA by ERRg mediates an inhibition of glycolysis.
We next tested the hypothesis that the expression of these
metabolic genes could be affected by the presence of
miR-378*. qRT-PCRdata indeed show thatmiR-378* expression
causes a decrease in transcript levels of key TCA cycle genes
while inhibition of endogenous miR-378* using a specific inhib-
itor causes an increase in the expression of many TCA cycle
genes (Figure 3D). Of the glycolytic genes, miR-378* decreases
HK2 levels and increases LDHD levels (Figure 3C).
Interestingly, not all of the known TCA cycle ERR target genes
were downregulated in response to miR-378*. It should be noted
that ERRa is present in abundance in these cells, and ERR
isoforms are known to compensate for each others’ absence
(Dufour et al., 2007). This indicates that the direct ERRg target
genes which are downregulated in response to miR-378*, CS,
SDHB, and FH could be specific genes for which ERRa cannot
compensate in response to downregulation of ERRg. We vali-
dated this hypothesis by using a siRNA specific for ERRa
(Figures 3B and 3D) and found that, while someERR target genes
respond in the same way to depletion of either ERRa or -g, such
as ACO2 and SUCLA2, ERRa is not capable of compensating for
depletion of ERRg in the case ofCS,SDHB, or FH. Of note,SDHB
and FH have recently been reported to act as tumor suppressors
(King et al., 2006), further implicating the function of this pathway
simultaneously in regulation of both metabolism and cancer. Of
the glycolytic genes tested in these conditions, LDHA responded
in an opposite manner to ERRa and -g depletion, while LDHB
levels decreased in response to depletion of both ERRs
(Figure 3C). Furthermore, these experiments suggest that
GABPA is downstream of ERRg, as it is downregulated in
response to miR-378* and similarly so in response to ERRg
knockdown (Figure 3D). Notably, GABPA increases slightly in
expression in response to ERRa knockdown, indicating that it
could be regulated by the ERRs in an isoform-specific fashion.
Taken together, these results suggest that miR-378* regulates
gene expression in a manner that represses oxidative metabo-
lism and, in so doing, favors glycolysis.
miR-378* Induces a Metabolic Shift in Cancer Cells
Wenext sought to determine if miR-378* was capable of inducing
a metabolic shift in cancer cells. First, short-term exposure to
miR-378* by transient transfection slightly but significantly
increases cell proliferation of BT-474 breast cancer cells (Fig-
ure 4A). Furthermore, induction of miR-378* caused an increase
of cellular lactate (Figure 4B) and a reduction of total cellular respi-
ration (Figure 4C). Knockdown of ERRg expression using a siRNA
generated a similar reduction in total cellular respiration
(Figure 4D). Cellular respiration is composed of nonmitochondrial
andmitochondrial components. InBT-474 cells,wedid not detect
any nonmitochondrial respiration. Mitochondrial respiration is
comprised of coupled and uncoupled respiration. Coupled respi-
ration is linked to ATP turnover, while uncoupled respiration is
linked toproton leak. IntroductionofmiR-378*decreasedcoupled
respiration by approximately a third (Figure 4E). ATP levels were
stable in cancer cells expressing miR-378* (Figure 4F), indicating
that the overall energy homeostasis was maintained.
We then confirmed that miR-378* induces a metabolic shift by
measuring cellular bioenergetics outputs in response toMetabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inc. 355
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Figure 3. Regulation of Metabolic Genes by
miR-378* and Its Target, ERRg, in Breast
Cancer Cells
(A) Standard ChIP of promoter and enhancer
elements confirms direct regulation of metabolic
genes by ERRg in human breast cancer cells.
Location relative to the transcriptional start site
and sequences of ERR response elements
(ERREs) are also indicated.
(B) Introduction of siRNAs targeting ESRRA and
ESRRG results in specific downregulation of
ERRa and ERRg, respectively, in BT-474 cells.
(C) Introduction ofmiR-378* or amiR-378* inhibitor
as well as siRNAs against ESRRA and ESRRG
results in specific regulation of glycolytic gene
mRNA levels in BT-474 cells as determined by
qRT-PCR and normalized to 18S and TUBA1A as
internal controls and compared to corresponding
control miR, miR inhibitor, or scramble siRNA
treatments.
(D) Same as in (C) for GABPA and TCA cycle
genes. Unpaired Student’s t test was used for
evaluation of statistical significance in (C) and
(D), in which data from one representative experi-
ment are shown. For all bar graphs, data are repre-
sented as the mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001.
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miRNA Control of the Warburg Effectinhibition of endogenousmiR-378* inBT-474 cells using amiRNA
inhibitor. Inhibition ofmiR-378* caused a decrease in cell number
(Figure 4G), a reduction in lactate production (Figure 4H), and an
increase in cellular respiration (Figure 4I). Mitochondrial content
of BT-474 cells treated with either miR-378* or the miRNA inhib-
itor was not significantly different from control cells (Figure S2).
Taken together, both gain- and loss-of-function studies validate
that miR-378* regulates the Warburg effect. These data indicate
that miR-378* displays the oncogenic characteristic of
promoting cell proliferation while simultaneously inducing
a metabolic shift away from oxidative metabolism.
In order to validate our model of miR-378* function in
a different model of breast cancer, we used parental mouse
mammary epithelial cells, NMuMG, as a control cell line and
the NT2196 cell line as an ex vivo model of ERBB2-induced
mammary tumorigenesis (Ursini-Siegel et al., 2007). Endoge-356 Cell Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inc.nous miR-378*, miR-378, and Ppargc1b
expression was upregulated in the
NT2196 cells expressing high levels of
ERBB2 as compared to the parental
NMuMG mammary cells (Figure 4J). We
next measured the endogenous levels of
the miR-378* downstream targets in
both cells lines (Figures 4K and 4L). Inter-
estingly, Gabpa mRNA levels were
unchanged between the two cell lines
(Figure 4K) but GABPA protein was
remarkably decreased in the NT2196
cells as compared to NMuMG cells
(Figure 4L). Esrrg mRNA expression was
too low to quantify accurately but ERRg
protein was decreased in NT2196 cellsas compared to NMuMG cells (Figure 4L). These results show
that ERRg and GABPA are direct targets of endogenous miR-
378* across different cell lines of mouse and human origin. In
addition, two of the three miR-378*- and ERRg-controlled TCA
cycle genes, Fh1 and Sdhb, were significantly downregulated
in NT2196 cells as compared to NMuMG cells (Figure 4K),
thereby recapitulating much of the effect of miR-378* on TCA
cycle genes identified in human breast cancer cells. Corre-
spondingly, NT2196 cells display the Warburg effect in compar-
ison to NMuMG cells, in that NT2196 cells produce more lactate
(Figure 4M) and have a decreased rate of respiration (Figure 4N).
Importantly, while both miR-378* and Ppargc1b expression is
increased by similar amounts in NT2196 cells compared to
NMuMGcells, the ERBB2-expressing cells display a shift toward
the Warburg effect, thereby overriding the ability of Ppargc1b to
promote oxidative metabolism.
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Figure 4. miR-378* Induces a Metabolic Shift in Breast Cancer Cells of Human and Mouse Origin
(A) Expression of miR-378* increases BT-474 cell proliferation.
(B) Increase in lactate levels upon expression of miR-378*.
(C) Total cellular respiration of BT-474 cells is reduced by expression of miR-378*.
(D) Total cellular respiration of BT-474 cells is reduced by expression of siESRRG.
(E) Introduction of miR-378* decreases mitochondrial coupled respiration. Total respiration is broken down into coupled (black) and uncoupled (white) compo-
nents.
(F) Effect of expression of miR-378* on ATP levels.
(G) Expression of a miR-378* inhibitor (miR-378*-I) decreases BT-474 cell proliferation.
(H) Decrease in lactate levels upon expression of miR-378*-I.
(I) Total cellular respiration of BT-474 cells is increased by expression of miR-378*-I.
(J) The murine mammary epithelial cell line (NMuMG) and an ex vivo NMuMG tumor cell line overexpressing the Neu receptor (NT2196) were assayed for
miR-378*, miR-378, and Ppargc1b expression levels by qRT-PCR and normalized to U6 or Arbp.
(K) Some key genes downstream of miR-378*, as detected by qRT-PCR, are downregulated at the mRNA level in NT2196 cells as compared to NMuMG cells.
Esrrg mRNA levels were detectable but too low to accurately quantitate. Arbp was used as an internal control.
(L) ERRg and GABPA protein levels are decreased in NT2196 cells as compared to NMuMG cells as measured by western blotting. RPLP0 was used as a loading
control. Arrow indicates band corresponding to ERRg.
(M) Increase in lactate levels in NT2196 cells as compared to NMuMG cells.
(N) Total cellular respiration is reduced in NT2196 cells as compared to NMuMG cells. Unpaired Student’s t test was used for evaluation of statistical significance
in (B), (F), (J), and (K) in which data from one representative experiment are shown. Paired Student’s t test was used for evaluation of significance in (A), (C), (D), (G),
(H), (I), (M), and (N) in which data from at least four independent experiments are shown. Lactate and ATP data are normalized to cell number. For all bar graphs,
data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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To determine the physiological relevance of miR-378* in breast
cancer, we performed in situ hybridization on sections of normal
breast tissue, tumors, and lymph node metastases with a probe
directed against miR-378*. Representative miR-378* staining on
a tissue microarray (TMA) containing 160 cores of tissue classi-
fied as normal, ductal carcinoma in situ (DCIS), tumor, or meta-
static lymph node is shown on Figure 5A. We scored miR-378*
expression in each core on a scale from 0 (no expression) to 3
(high expression) based on colorimetric signal intensity
(Figure 5B). The mean score of normal tissue was significantly
lower than that of DCIS, tumor, or lymph node tissue, indicating
that miR-378* expression increases as tissue progresses from
a normal to a cancerous state. Indeed, 60% of the normal
tissue cores scored 0, suggesting that in most cases miR-378*Cellis only expressed after the onset of cancerous progression. In
addition, the mean score of metastatic lymph node tissue was
significantly higher than that of both DCIS and tumor tissue. To
analyze the data by matched samples, cores from the same
patient but with different pathologies were grouped, and the cor-
responding scores were compared (Table 1). A similar trend was
recapitulated as with the unmatched samples; themean score of
normal cores was significantly lower than that of any other type
of core. The mean score of tumor cores was significantly higher
than that of matched DCIS cores, indicating that within a patient,
as a cancer progresses from DCIS to tumor, miR-378* expres-
sion increases. The means of matched DCIS and tumor cores
are smaller than that of the corresponding lymph node cores,
but the differences are not significant due to the small sample
size of these groups.Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inc. 357
Figure 5. Expression of miR-378* in Normal and Cancerous Breast
Tissue
(A) Representative images of normal and cancerous breast tissue subjected to
in situ hybridization with a probe directed against miR-378*. DCIS, ductal
carcinoma in situ. Nuclear staining was performed using Nuclear Fast Red,
and visualization of miR-378* expression was generated by a colorimetric
reaction resulting in purple coloring. Images are at 203 magnification.
(B) Quantification of miR-378* expression as assessed by in situ hybridization
of a TMA containing 160 cores of distinct normal, cancerous, and metastatic
breast samples. Levels of miR-378* expression were scored from 0 (absent,
blue) to 3 (highly expressed, red). Number (n) of samples for each type of
breast tissue is indicated on top of each column. Significance was determined
using the Mann-Whitney test. X = mean.
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358 Cell Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier InDISCUSSION
The molecular mechanisms that govern a shift in energy metab-
olism to the advantage of cancer cells are complex and only
partially understood. In this study, wedemonstrate that a specific
miRNA, miR-378*, plays an important role in reprogramming
breast cancer cells such that TCA cycle activity is reduced and
the cells are less dependent on OXPHOS to fulfill their energy
demands. miR-378*, whose expression is regulated by the
ERBB2 signaling pathway, achieves this metabolic shift by
suppressing the expression of two key regulators of energy
metabolism, ERRg and GABPA. This study shows that a miRNA
can be both a component and a regulator of a well-integrated
transcriptional pathway, and that cancer cells can specifically
exploit the PGC-1b/ERR/GABPA bioenergetics pathway for
growth and proliferation (Figure 6A).
Since miR-378* affects cellular respiration in an opposite
manner from PGC-1b, it can appear that these two cotran-
scribed molecules function in a contradictory manner. However,
when taken together with knowledge regarding the function of
these two molecules and recent literature on transcriptional
feedback loops, the miR-378*/PGC-1b relationship can be inte-
grated in a cohesive mechanism. First, miR-378* causes
a decrease in cellular respiration and an increase in lactate
production in breast cancer cells. Overexpression of PGC-1b
has been shown to induce cellular respiration (St-Pierre et al.,
2003), yet its effect on lactate production has not been shown.
Studies based on PGC-1b knockout mice are limited in terms
of their contribution to what we understand about the relation-
ship between miR-378* and PGC-1b, as miR-378* is still ex-
pressed in these mice (Figure S3). To shed light on the role of
PGC-1b in breast cancer cells, we knocked down its expression
in breast cancer cells using siRNA. We observed a decrease in
genes required for cellular respiration and glycolysis
(Figure S4), indicating that PGC-1b is required for bothmetabolic
processes. Thus, the function of PGC-1b is not to inhibit theWar-
burg effect but to maintain overall metabolic gene expression.
This would make miR-378* the ‘‘decision maker’’ in terms of
which metabolic pathway is used most dominantly, while not
diminishing the importance of PGC-1b for allowing cellular meta-
bolic function. Second, since miR-378* is able to modulate the
relative levels of PGC-1b partners, it can directly influence the
metabolic function of PGC-1b. In essence, the role of PGC-1b
as a coactivator only allows it to dictate cellular programs that
its available transcriptional binding partners are capable ofmedi-
ating. By targeting and regulating specific partners of PGC-1b,
miR-378* amplifies its ability to choose which metabolic path-
ways dominate under specific physiological cues. This hypoth-
esis is supported by our data from the NMuMG/NT2196
ex vivo cell system (Figures 4J–4N) in which the Warburg effect
is induced in a context where both miR-378* and PPARGC1B
expression levels are endogenously elevated in response to
Neu expression. Third, feedforward loops are the most common
network motifs in transcription networks (Alon, 2007). In partic-
ular, the incoherent type 1 feedforward loop motif (Figure 6B),
which describes the miR-378*/PGC-1b/ERRg relationship
(Figure 6C), functions as a pulse generator and response accel-
erator in biological systems. It has been demonstrated that the
incoherent type 1 feedforward loop motif network responsec.
Table 1. Expression of miR-378* in Matched Breast Samples
Normal DCIS Tumor Lymph Node s P Value #
DCIS versus normal 0.65 1.29 0.65 0.061 17
Tumor versus normal 0.63 1.63 1.00 <0.0001 30
Lymph node versus normal 0.83 2.33 1.50 0.021 6
Tumor versus DCIS 1.13 1.67 0.54 0.046 24
Lymph node versus DCIS 2.25 2.50 0.25 NS 4
Lymph node versus tumor 1.75 2.38 0.63 NS 8
Values represent mean score for miR-378* expression signal.s, difference between matched groups; #, number of patients.
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on its absolute level, a trait important for cellular signaling (Goen-
toro et al., 2009). Taken together, the type of feedback loop in
which miR-378* and PGC-1b participate is not only very
common in biology, but the seemingly contradictory functions
of two molecules within this same loop actually allow for
a specific type of network response.
The observation that decreased cell respiration in response to
miR-378* is accompanied by increased cell number suggests
that other biochemical pathways could be activated to allow for
sufficient anapleurosis. For example, miR-378* could promote
glycolysis and simultaneously increase glutaminolytic flux (Jones
and Thompson, 2009). However, we did not observe any major
changes in the expression of key enzymes involved in glutamine
metabolism in response to modulation of miR-378* levels
(Figure S5). These results indicate that the remaining mitochon-
drial function may be adequate to support the anapleurotic reac-
tions necessary for enhanced cell proliferation.
It had previously been shown that a genomic construct coex-
pressing the miR-378*/miR-378 sequence causes an increase in
cell survival and a decrease in Caspase 3 activity in U87 cells,
and injection of these cells into nude mice induces tumor forma-
tion, indicating the ability of this hairpin to promote oncogenesis
(Lee et al., 2007). Our TMA data quantify miR-378* expression in
breast cancer, and show that miR-378* expression increases
with tumor progression in a statistically significant manner (Fig-
ure 5B). In addition, ERBB2 positivity status of the DCIS samplesA
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Figure 6. Schematic Representations of the Metabolic Pathways Influ
Network Motif
(A) Presence of the oncogene ERBB2 leads to coexpression of PPARGC1B and
378* is accompanied by a reduction in the expression of genes in the TCA cycle.
(TFs) to promote other functions, including glycolysis. Overall, miR-378* expressi
metabolism in the presence of available oxygen (Warburg effect) as represented
(B) Incoherent feedforward loop type 1 displaying opposite regulation of Z by fac
(C) Incoherent feedforward loop type 1 illustrating the functional relationship betw
lators influencing the activity of ERRg.
Cellshowed a trend (p = 0.0996) of increased miR-378* expression.
The mean miR-378* expression within the ERBB2-positive
samples is also higher in normal and tumor tissue of patients
whose cancer recurred compared to those whose cancer did
not recur. Small sample size limits statistical significance as
matched samples are rare, but these results indicate another
interesting trend of miR-378* expression in breast cancer.
The observation that miR-378* specifically targets ERRg
provides a possible mechanism to account for the correlative
opposing roles that ERRa and -g play as negative and positive
breast cancer biomarkers, respectively (Ariazi et al., 2002; Su-
zuki et al., 2004). ERR regulation of target genes can depend
on many factors including tissue context and the presence of
cofactors. In this respect, our results suggest that ERRa/PGC-
1b favors activation of the glycolytic pathway while ERRg/
PGC-1b promotes oxidative metabolism in cancer cells, and
that modulation of ERR isoform levels by miR-378* allows it to
promote one pairing over the other. Less well studied are the
differences between the ERR isoforms with respect to regulation
of target gene levels. While Dufour et al. (2007) have shown that
ERRa and ERRg can regulate the same direct target genes, the
SHP promoter is activated by ERRg but not ERRa or ERRb
(Sanyal et al., 2002). In breast cancer cells, we observed different
responses of specific metabolic genes to ERRa and ERRg. This
suggests that the transcriptional output of each ERR is not equiv-
alent, thus adding to the complexity of their function. Taken
together with their opposing roles in breast cancer, it will beCB
cell proliferation
Warburg effect
mption
PGC-1β
miR-378*
ErbB2
ERRγ
X
Y
Z
Signal
Feedforward loop
(incoherent type I)
enced by miR-378* and the PGC-1b/miR-378*/ERRg Transcriptional
miR-378*. Loss of expression of ERRg and GABPA through the action of miR-
PGC-1b remains present to coactivate ERRa and/or other transcription factors
on results in a shift from aerobic, oxidative metabolism (OXPHOS) to glycolytic
by an increase in lactate levels and a reduction in oxygen consumption.
tors X and Y. Wavy arrow indicates input regulatory signal for factor X.
een ERBB2 (regulatory signal), PGC-1b, and miR-378* as transcription modu-
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miRNA Control of the Warburg Effectimportant to further elucidate the functional differences between
these two isoforms in breast cancer and metabolic diseases.
EXPERIMENTAL PROCEDURES
Cell Culture
In general, cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10%FBS, sodium pyruvate, l-glutamine, and anti-
biotics and weremaintained in 5%CO2 at 37
C. NMuMGcells were cultured in
media with additional supplements of HEPES and insulin, and NT2196 cells
were also cultured with puromycin.
Adenovirus Generation and Infection
The human miR-378* genomic sequence with 150 bp on either side of the
miRNA hairpin was cloned into an adenovirus vector. Virus was produced by
Qbiogene, and cells were infected at moi = 25.
siRNA Experiments
Cells were transfected using HiPerFect according to the reverse-transfection
protocol with 50 nM ERBB2 and ESRRA siRNA and 100 nM ESRRG and
PPARGC1b siRNA (or the corresponding control siRNA). For optimal protein
knockdown, cells were harvested 48 hr posttransfection for siERBB2 and
siESRRA, 60 hr posttransfection for siPPARGC1b experiments, and 6 days
posttransfection for siESRRG experiments.
Reporter Construct Cloning and Transfection
Regions or mutated regions of the human ESRRG and GABPA 30UTRs pre-
dicted to be targeted by miR-378* were cloned into the phRL-TK(Int-) reporter
vector at the 30UTR position relative to the Renilla luciferase gene. Reporter
constructs were cotransfected with miR-378* Mimic or control miRNA Mimic
into COS-1 cells using Lipofectamine 2000.
miRNA and miRNA Inhibitor Transfection
Twenty-four hours after plating, cells were transfected using Lipofectamine
2000 with miRNA Mimic (Dharmacon) at a final concentration of 75–100 nM
depending on the experimental conditions or miRNA Inhibitor at a final
concentration of 90–110 nM depending on the experimental conditions (see
the Supplemental Information). Typically, experiments were harvested
2 days posttransfection; however, miRNA inhibitor experiments for protein
detection were harvested 6 days posttransfection and 4 days posttransfection
for RNA, cell proliferation, lactate, and respiration experiments.
RNA Isolation, Reverse Transcription, and Real-Time
Quantitative PCR
RNA was typically isolated using the QIAGEN miRNeasy Kit, during which
DNase treatment was performed. For detection of cDNA from mRNA tran-
scripts, reverse transcription was performed using Invitrogen reagents, and
real-time qRT-PCR was carried out in a LightCycler instrument (Roche).
miRNA levels were detected using Taqman miRNA qRT-PCR following the
manufacturer’s instructions (Applied Biosystems), and the corresponding
real-time qRT-PCR reactions were carried out in a Corbett Research Rotor-
Gene instrument.
Western Blots
Proteinwas harvestedwith RIPAbuffer and quantified, and then resolved on an
SDS-PAGE gel. Protein was then transferred onto a membrane, blocked, and
then incubated with primary antibody. After three washes, membranes were
incubated with secondary antibody. After three more washes, proteins were
detected using chemiluminescence. The loading control protein was either de-
tected on the same membrane simultaneously with the target proteins if size
differences allowed, or the membranes were stripped and reprobed to detect
the loading control. See the Supplemental Information for antibody details.
Chromatin Immunoprecipitation
Cells were crosslinked with formaldehyde and sonicated. The material was
precleared before being immunoprecipitated with antibody (or without, as
control). After addition of beads, and a subsequent series of washes, samples360 Cell Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inwere decrosslinked and purified, and tested for enrichment of DNA segments
by real-time qRT-PCR.
Lactate Detection Assay
Lactate was measured using the Lactate Assay Kit II (BioVision) and the
Lactate Assay Kit (Eton Bioscience Inc.).
Measurement of ATP
The ATP Bioluminescence Assay Kit HS was used to detect cellular ATP.
Respiration Assay and Cell Proliferation Assay
Cells were trypsinized, washed, and resuspended in supplemented PBS. Cell
viability was determined and cells were counted. Onemillion cells were placed
into the chamber of a Clark-type electrode, and cellular respiration was
measured. Oligomycin and myxothiazol were used to identify rates of ATP
turnover and nonmitochondrial respiration, respectively.
In Situ Hybridization on FFPE Section
Tissue sections were hybridized with double-DIG-labeled probe, which was
recognized by an anti-DIG-HRP antibody. The TSA Plus DNP AP System (Per-
kinElmer) was used to amplify the signal, the NBT/BCIP reagent (Roche)
produced the colorimetric reaction, and Nuclear Fast Redwas used as a coun-
terstain.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, five tables, and Supplemental
Experimental Procedures and can be found with this article at doi:10.1016/j.
cmet.2010.09.002.
ACKNOWLEDGMENTS
We thank T. Duchaine for helpful discussion and critical reading of the manu-
script; W. Muller for the NMuMG and NT2196 cell lines; A. Dydensborg for
guidance with the MitoTracker experiments; and V. Chenard, J.A. Bader,
and M. Souleimanova for technical assistance. We thank R.M. Evans (Salk
Institute) for the Ppargc1b knockout mice. L.J.E. is a recipient of studentships
from the McGill University Health Centre Research Institute and the Fonds de
la Recherche en Sante´ du Que´bec (FRSQ). M.-C.P. is a recipient of a student-
ship from the National Science and Engineering Research Council of Canada.
V.G. and J.St-P. are supported by the Canadian Institutes for Health
Research (grants MOP-64275, MOP-77763, MOP-84227, and IC1-102947).
M.P., J.St-P., and V.G. are supported by an institutional grant from the
FRSQ to the Morris and Rosalind Goodman Cancer Research Centre. This
work was also supported by grants from the Que´bec Breast Cancer Founda-
tion (QBCF) and the Banque de tissu et de donne´es of the Re´seau de la re-
cherche sur le cancer (RRCancer) of the FRSQ (to M.P.), and a Program
Project grant from the Canadian Cancer Society Research Institute/Terry
Fox Foundation (to M.P. and V.G.). M.P. holds the Diane and Sal Guerrera
Chair in Cancer Genetics at McGill University.
Received: August 11, 2009
Revised: April 7, 2010
Accepted: June 23, 2010
Published: October 5, 2010
REFERENCES
Alaynick, W.A., Kondo, R.P., Xie, W., He, W., Dufour, C.R., Downes, M.,
Jonker, J.W., Giles, W., Naviaux, R.K., Gigue`re, V., et al. (2007). ERRg directs
and maintains the transition to oxidative metabolism in the post-natal heart.
Cell Metab. 6, 16–24.
Alon, U. (2007). Network motifs: theory and experimental approaches. Nat.
Rev. Genet. 8, 450–461.
Ariazi, E.A., Clark, G.M., and Mertz, J.E. (2002). Estrogen-related receptor
a and estrogen-related receptor g associate with unfavorable and favorable
biomarkers, respectively, in humanbreast cancer. Cancer Res. 62, 6510–6518.c.
Cell Metabolism
miRNA Control of the Warburg EffectCervera, A.M., Apostolova, N., Crespo, F.L., Mata, M., and McCreath, K.J.
(2008). Cells silenced for SDHB expression display characteristic features of
the tumor phenotype. Cancer Res. 68, 4058–4067.
Charest-Marcotte, A., Dufour, C.R., Wilson, B.J., Tremblay, A.M., Eichner,
L.J., Arlow, D.H., Mootha, V.K., and Gigue`re, V. (2010). The homeobox protein
Prox1 is a negative modulator of ERRa/PGC-1a bioenergetic functions. Genes
Dev. 24, 537–542.
Deblois, G., Hall, J.A., Perry, M.-C., Laganie`re, J., Ghahremani, M., Park, M.,
Hallett, M., and Gigue`re, V. (2009). Genome-wide identification of direct target
genes implicates estrogen-related receptor a as a determinant of breast
cancer heterogeneity. Cancer Res. 69, 6149–6157.
Dufour, C.R., Wilson, B.J., Huss, J.M., Kelly, D.P., Alaynick, W.A., Downes, M.,
Evans, R.M., Blanchette, M., and Gigue`re, V. (2007). Genone-wide orchestra-
tion of cardiac functions by orphan nucler receptors ERRa and g. Cell Metab.
5, 345–356.
Fantin, V.R., St-Pierre, J., and Leder, P. (2006). Attenuation of LDH-A expres-
sion uncovers a link between glycolysis, mitochondrial physiology, and tumor
maintenance. Cancer Cell 9, 425–434.
Gigue`re, V. (2008). Transcriptional control of energy homeostasis by the
estrogen-related receptors. Endocr. Rev. 29, 677–696.
Goentoro, L., Shoval, O., Kirschner, M.W., and Alon, U. (2009). The incoherent
feedforward loop can provide fold-change detection in gene regulation. Mol.
Cell 36, 894–899.
Jones, R.G., and Thompson, C.B. (2009). Tumor suppressors and cell metab-
olism: a recipe for cancer growth. Genes Dev. 23, 537–548.
Kim, Y., and Kim, V. (2007). Intronic miRNA. EMBO J. 26, 775–783.
King, A., Selak, M.A., and Gottlieb, E. (2006). Succinate dehydrogenase and
fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene
25, 4675–4682.
Lee, D.Y., Deng, Z., Wang, C.H., and Yang, B.B. (2007). MicroRNA-378
promotes cell survival, tumor growth, and angiogenesis by targeting SuFu
and Fus-1 expression. Proc. Natl. Acad. Sci. USA 104, 20350–20355.
Lin, J., Handschin, C., and Spiegelman, B.M. (2005).Metabolic control through
the PGC-1 family of transcription coactivators. Cell Metab. 1, 361–370.
Ma, L., and Weinberg, R.A. (2008). MicroRNAs in malignant progression. Cell
Cycle 7, 570–572.
Mootha, V.K., Handschin, C., Arlow, D., Xie, X., St Pierre, J., Sihag, S.,
Yang, W., Altshuler, D., Puigserver, P., Patterson, N., et al. (2004). ERRaCelland GABPAa/b specify PGC-1a-dependent oxidative phosphorylation
gene expression that is altered in diabetic muscle. Proc. Natl. Acad. Sci.
USA 101, 6570–6575.
Sanyal, S., Kim, J.Y., Kim, H.J., Takeda, J., Lee, Y.K., Moore, D.D., and
Choi, H.S. (2002). Differential regulation of the orphan nuclear receptor
SHP gene promoter by orphan nuclear receptor ERR isoforms. J. Biol.
Chem. 277, 1739–1748.
Schreiber, S.N., Emter, R., Hock, M.B., Knutti, D., Cardenas, J., Podvinec, M.,
Oakeley, E.J., and Kralli, A. (2004). The estrogen-related receptor alpha (ERRa)
functions in PPARg coactivator 1a (PGC-1a)-induced mitochondrial biogen-
esis. Proc. Natl. Acad. Sci. USA 101, 6472–6477.
Sonoda, J., Laganie`re, J., Mehl, I.R., Barish, G.D., Chong, L.W., Li, X., Schef-
fler, I.E., Mock, D.C., Bataille, A.R., Robert, F., et al. (2007). Nuclear receptor
ERRa and coactivator PGC-1b are effectors of IFN-g induced host defense.
Genes Dev. 21, 1909–1920.
St-Pierre, J., Lin, J., Krauss, S., Tarr, P.T., Yang, R., Newgard, C.B., and Spie-
gelman, B.M. (2003). Bioenergetic analysis of peroxisome proliferator-acti-
vated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and
PGC-1beta) in muscle cells. J. Biol. Chem. 278, 26597–26603.
Suzuki, T., Miki, Y., Moriya, T., Shimada, N., Ishida, T., Hirakawa, H., Ohuchi,
N., and Sasano, H. (2004). Estrogen-related receptor a in human breast carci-
noma as a potent prognostic factor. Cancer Res. 64, 4670–4676.
Tremblay, A.M., Dufour, C.R., Ghahremani, M., Reudelhuber, T.L., and
Gigue`re, V. (2010). Physiological genomics identifies estrogen-related
receptor a as a regulator of renal sodium and potassium homeostasis
and the renin-angiotensin pathway. Mol. Endocrinol. 24, 22–32.
Ursini-Siegel, J., Rajput, A.B., Lu, H., Sanguin-Gendreau, V., Zuo, D., Papava-
siliou, V., Lavoie, C., Turpin, J., Cianflone, K., Huntsman, D.G., et al. (2007).
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor
development. Mol. Cell. Biol. 27, 6361–6371.
Ventura, A., and Jacks, T. (2009). MicroRNAs and cancer: short RNAs go
a long way. Cell 136, 586–591.
Warburg, O. (1956). On respiratory impairment in cancer cells. Science 124,
269–270.
Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I.,
Dang, C.V., and Semenza, G.L. (2007). HIF-1 inhibits mitochondrial biogenesis
and cellular respiration in VHL-deficient renal cell carcinoma by repression of
C-MYC activity. Cancer Cell 11, 407–420.Metabolism 12, 352–361, October 6, 2010 ª2010 Elsevier Inc. 361
